Zucchelli P, Santoro A, Ferrari G, Spongano M
Divisione di Nefrologia e Dialisi Malpighi, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Blood Purif. 1990;8(1):14-22. doi: 10.1159/000169920.
Bicarbonate dialysis has several clinical advantages compared to conventional acetate hemodialysis. However, the use of bicarbonate in the dialysate requires complicated hardware with considerable maintenance and servicing. We have developed a new dialysis technique, a modification of hemodiafiltration, called acetate-free biofiltration (AFBF), with no base replacement agents in the dialysate and with the infusion of bicarbonate solution in postdilution fluid. This study consisted of two parts, an acute phase (8 dialysis patients) and a chronic phase (4 patients) lasting up to 12 months. In the first phase we evaluated the effects of different amounts of infused bicarbonate (from 751 to 1,002 mEq per session) on acid-base balance. The best correction of uremic acidosis was obtained with the infusion of 900-1,000 HCO3 mEq during a 3-hour AFBF. There was a significant (p less than 0.0001) positive correlation between infused and gained bicarbonate. In the chronic part, 880-910 HCO3 mEq was infused per session and there was an increase in mean pretreatment plasma bicarbonate from 18.1 +/- 2.2 upon starting to 22.8 +/- 0.4 mEq/l by the end of the 12-month period. A very low incidence of intradialytic hypotension and stable serum chemistries were achieved with this technique as compared with standard hemodialysis despite a reduction of 3 h in weekly treatment time. AFBF is an easy-to-use, safe alternative to bicarbonate dialysis thanks to the absence of pyrogen reactions and comparatively low-cost maintenance.
与传统的醋酸盐血液透析相比,碳酸氢盐透析具有若干临床优势。然而,在透析液中使用碳酸氢盐需要复杂的硬件设备,且维护和保养工作相当繁重。我们开发了一种新的透析技术,即血液透析滤过的改良方法,称为无醋酸盐生物滤过(AFBF),该方法在透析液中不使用碱基替代剂,而是在后置稀释液中输注碳酸氢盐溶液。本研究包括两个部分,急性期(8例透析患者)和慢性期(4例患者),慢性期持续长达12个月。在第一阶段,我们评估了不同量的输注碳酸氢盐(每次透析751至1002 mEq)对酸碱平衡的影响。在3小时的AFBF过程中,输注900 - 1000 HCO3 mEq可实现对尿毒症酸中毒的最佳纠正。输注的碳酸氢盐与获得的碳酸氢盐之间存在显著的正相关(p小于0.0001)。在慢性期部分,每次透析输注880 - 910 HCO3 mEq,在12个月疗程结束时,平均透析前血浆碳酸氢盐从开始时的18.1±2.2 mEq/L增加至22.8±0.4 mEq/L。与标准血液透析相比,尽管每周治疗时间减少了3小时,但该技术实现了透析中低血压的发生率极低且血清化学指标稳定。由于不存在热原反应且维护成本相对较低,AFBF是一种易于使用且安全的碳酸氢盐透析替代方法。